Compare TENX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TENX | COCH |
|---|---|---|
| Founded | 1967 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2M | 47.1M |
| IPO Year | 2001 | N/A |
| Metric | TENX | COCH |
|---|---|---|
| Price | $11.75 | $0.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $29.67 | $6.00 |
| AVG Volume (30 Days) | ★ 605.5K | 118.1K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.34 | $0.36 |
| 52 Week High | $18.38 | $1.91 |
| Indicator | TENX | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 42.60 |
| Support Level | $10.83 | $0.63 |
| Resistance Level | $14.15 | $0.73 |
| Average True Range (ATR) | 0.95 | 0.04 |
| MACD | -0.28 | -0.00 |
| Stochastic Oscillator | 7.00 | 17.62 |
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.